Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-26 @ 10:19 PM
Ignite Modification Date: 2025-12-26 @ 10:19 PM
NCT ID: NCT04677712
Description: None
Frequency Threshold: 0
Time Frame: Day 1 (after dosing) through Day 71
Study: NCT04677712
Study Brief: Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Cohort 1: CCH-aaes CCH-aaes was administered to both buttocks without mitigation treatment (control group). 0 None 0 7 6 7 View
Cohort 2: CCH-aaes + Compression Garment CCH-aaes was administered to both buttocks with compression garments as the mitigation treatment. 0 None 0 8 8 8 View
Cohort 3:CCH-aaes + Instant Cold Packs CCH-aaes was administered to both buttocks with instant cold packs applied to the right buttock only for 5-10 minutes post injection as the mitigation treatment. 0 None 0 9 9 9 View
Cohort 4: CCH-aaes + Arnica Gel Patches (OcuMend) CCH-aaes was administered to both buttocks with arnica gel patches (OcuMend) applied to the right buttock only immediately after injection and BID for 2 days as the mitigation treatment. 0 None 0 9 9 9 View
Cohort 5: CCH-aaes + INhance Post-Injection Serum With TriHex Technology® CCH-aaes was administered to both buttocks with INhance Post-Injection Serum with TriHex Technology® applied to the right buttock only QID for up to 7 days as the mitigation treatment. 0 None 0 8 8 8 View
Cohort 6: CCH-aaes + PDL CCH-aaes was administered to both buttocks with PDL applied once to the right buttock only between Days 1-7 post injection as the mitigation treatment. 0 None 0 7 6 7 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Injection site bruising SYSTEMATIC_ASSESSMENT General disorders MedDRA 22.1 View
Injection site discolouration SYSTEMATIC_ASSESSMENT General disorders MedDRA 22.1 View
Injection site nodule SYSTEMATIC_ASSESSMENT General disorders MedDRA 22.1 View
Injection site pain SYSTEMATIC_ASSESSMENT General disorders MedDRA 22.1 View
Injection site pruritus SYSTEMATIC_ASSESSMENT General disorders MedDRA 22.1 View
Contusion SYSTEMATIC_ASSESSMENT Injury, poisoning and procedural complications MedDRA 22.1 View